{
  "id": "6026de661cb411341a0000d1",
  "type": "yesno",
  "question": "Are there small molecule CGRPs under development for the treatment of migraine?",
  "ideal_answer": "Yes, there are several small molecule CGRPs under development for the treatment of migraine.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28644160"
  ],
  "snippets": [
    {
      "text": "Meanwhile, 1 small-molecule CGRP receptor antagonist (ubrogepant, MK-1602) is currently in phase 3 studies for the acute treatment of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28644160",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Several other small-molecular CGRP receptor antagonists are in earlier stages of development for acute migraine treatment or prevention. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28644160",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}